ENECADIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H28FN3O
Molecular Weight	357.4649
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC(OCCCCCN2CCCCC2)=CC(=N1)C3=CC=C(F)C=C3

InChI

InChIKey=SZSHJTJCJOWMHM-UHFFFAOYSA-N

InChI=1S/C21H28FN3O/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25/h8-11,16H,2-7,12-15H2,1H3

HIDE SMILES / InChI

Molecular Formula	C21H28FN3O
Molecular Weight	357.4649
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16100702 | https://adisinsight.springer.com/drugs/800009089 | https://www.ncbi.nlm.nih.gov/pubmed/12676377 | https://www.ncbi.nlm.nih.gov/pubmed/15678048 | https://www.ncbi.nlm.nih.gov/pubmed/16187036 | https://clinicaltrials.gov/ct2/show/NCT00331721

Enecadin (NS 7 or ZK 228326) is a voltage-dependent sodium and calcium channel blocker. Enecadin is a neuroprotective agent demonstrated efficacy in animal models of ischemic injury of brain, spinal cord and retina. Enecadin was undergoing phase II development in stroke with PAION in Germany. Enecadin development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-sensitive sodium channel 7 Target ID: CHEMBL2362985 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18377333	Blocker 537
Voltage-gated calcium channel 37 Target ID: CHEMBL2363032 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18377333	Blocker 537

PubMed

Title	Date	PubMed
Cerebroprotective action of a Na+/Ca2+ channel blocker NS-7. I. Effect on the cerebral infarction and edema at the acute stage of permanent middle cerebral artery occlusion in rats.	2001 Jan 26	11164779
A novel voltage-sensitive Na(+) and Ca(2+) channel blocker, NS-7, prevents suppression of cyclic AMP-dependent protein kinase and reduces infarct area in the acute phase of cerebral ischemia in rat.	2002 Jan 4	11744000
Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys.	2003	14558434
Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.	2005 Jun	15778734

Patents

Sample Use Guides

In Vitro Use Guide

In rat dorsal root ganglion neurones, NS-7 (0.3-100 microM) inhibited the whole-cell Ba(2+) currents (IBa) in a voltage-dependent manner, in which the compound more potently blocked the IBa elicited from the holding potential of -40 mV than that induced from -80 mV.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:01:10 GMT 2023` Edited by `admin` on `Fri Dec 15 16:01:10 GMT 2023`
Record UNII	VR034VW8OG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENECADIN

Official Name

English

Enecadin [WHO-DD]

Common Name

English

4-(4-FLUOROPHENYL)-2-METHYL-6-((5-(PIPERIDIN-1-YL)PENTYL)OXY)PYRIMIDINE

Systematic Name

English

enecadin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509